When to Start Levothyroxine Based on Thyroid Profile
Initiate levothyroxine immediately for overt hypothyroidism (elevated TSH with low free T4), for subclinical hypothyroidism with TSH >10 mIU/L, and for any pregnant woman with elevated TSH regardless of level.
Overt Hypothyroidism
Start levothyroxine without delay when TSH is elevated AND free T4 is below the reference range 1. This represents clear thyroid failure requiring replacement therapy.
Starting doses:
- Healthy adults <60 years without cardiac disease: Full replacement at 1.6 mcg/kg/day 1, 2
- Adults >60 years or with cardiac disease/risk: Start low at 12.5-50 mcg/day and titrate slowly every 6-8 weeks 1
- Pediatric patients: Age-based dosing from 10-15 mcg/kg/day (0-3 months) down to 1.6 mcg/kg/day (growth complete) 1
Subclinical Hypothyroidism (Elevated TSH, Normal Free T4)
The decision to treat depends critically on the TSH level:
TSH >10 mIU/L
Levothyroxine therapy is reasonable and should be initiated 3. The 5% annual progression rate to overt hypothyroidism and potential prevention of symptoms justify treatment, though evidence for mortality benefit remains lacking 3.
Starting dose: 25-75 mcg daily depending on TSH elevation 4, 5. A practical approach: 25 mcg for TSH 10-30 mIU/L, 50 mcg for TSH 30-100 mIU/L, 75 mcg for TSH >100 mIU/L 5.
TSH 4.5-10 mIU/L
Do NOT routinely treat 3. The evidence does not support clear benefits, and the panel explicitly recommends against routine levothyroxine treatment in this range 3.
Management approach:
- Monitor with repeat thyroid function tests every 6-12 months 3
- Consider a trial of levothyroxine (25-50 mcg) ONLY if the patient has clear hypothyroid symptoms 3
- Continue therapy only if there is unequivocal symptomatic improvement 3
- Understand that distinguishing true therapeutic effect from placebo is difficult, and likelihood of benefit is small 3
Critical caveat: The guidelines acknowledge this is controversial, as some patients may have symptoms, but emphasize that insufficient evidence exists to expect therapeutic benefit 3. The inconvenience, expense, and potential risks (14-21% develop subclinical hyperthyroidism) must be weighed carefully 3.
Pregnancy: Special Considerations
Treat ANY elevated TSH in pregnancy or women planning pregnancy immediately 3. This is non-negotiable.
Indications for treatment:
- Pre-existing hypothyroidism: Increase dose by 30% (take 9 doses weekly instead of 7) as soon as pregnancy confirmed 2
- New diagnosis with TSH ≥10 mIU/L: Start 1.6 mcg/kg/day 1
- New diagnosis with TSH <10 mIU/L: Start 1.0 mcg/kg/day 1
Target TSH levels by trimester:
Monitor TSH every 4 weeks during first half of pregnancy and at 26-32 weeks 4, 1. The rationale is preventing fetal wastage and neuropsychological complications in offspring, even though intervention trials are lacking 3. The benefit-risk ratio strongly favors treatment 3.
Monitoring After Initiation
Recheck TSH and free T4 at 4-8 weeks after starting therapy or any dose change 4, 1. Peak therapeutic effect may not occur for 4-6 weeks 1. Do not adjust doses more frequently than every 4-6 weeks 1.
Target for primary hypothyroidism: Normalize TSH to reference range 1
Target for secondary/tertiary hypothyroidism: TSH is unreliable; use free T4 and target the upper half of normal range 1
Common Pitfalls to Avoid
Do not treat based on symptoms alone without biochemical confirmation 4. Thyroid hormones should never be used for symptom relief in euthyroid individuals.
Do not over-treat subclinical hypothyroidism with TSH 4.5-10 mIU/L - the guidelines are clear this group should NOT receive routine treatment 3.
Do not start full replacement doses in elderly or cardiac patients - this can precipitate atrial fibrillation or cardiac ischemia 1.
Do not miss pregnancy - any woman of childbearing age with hypothyroidism needs immediate dose adjustment if pregnant 3, 4.
Do not use TSH to monitor secondary hypothyroidism - it will be misleading; use free T4 instead 1.